Exelon Corporation Common Stock vs Summit Therapeutics Inc — how do they compare? Exelon Corporation Common Stock trades at $41.73 (market cap $42.99B), while Summit Therapeutics Inc trades at $17.6 (market cap $13.71B). The key difference: Exelon Corporation Common Stock is far larger — about 3.1× Summit Therapeutics Inc's market cap, and Exelon Corporation Common Stock pays a 4.03% dividend while Summit Therapeutics Inc pays none. Which is the better fit depends on your goals.
| EXC | SMMT | |
|---|---|---|
Market Cap | $42.99B | $13.71B |
Volume | 7,570,408 | 6,173,057 |
Sector | Utilities | Health |
52-Week High | $50.29 | $26.38 |
52-Week Low | $40.20 | $12.43 |
Enterprise Value | $93.85B | $13.04B |
Dividend Yield | 4.03% | — |
Typical Hold Time | — | 16 Days |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Summit Therapeutics (SMMT) trades at $17.59, down 2.01% on the day, amid mixed earnings performance but strong analyst support with a consensus price target of $29.33. The stock shows a bullish technical signal from moving averages, with key support at $17 and resistance at $18. Recent news highlights a major $2 billion strategic investment from AstraZeneca and expanded clinical collaborations, boosting investor optimism despite current negative profitability metrics.
The outlook for SMMT is heavily driven by clinical progress and partnerships, offering significant upside if drug trials succeed, but carries high risk due to substantial losses, negative cash flow from operations, and reliance on positive trial outcomes. Investors should weigh the potential rewards against the company's current financial health and execution risks.
Trailing returns across standard periods
Latest headlines on both assets
Exelon is the parent company of six regulated electric and natural gas utilities. Its utilities include Atlantic City Electric, BGE, ComEd, Delmarva Power, PECO, and Pepco.
Read more on EXC →Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →